← Back to Search

Monoclonal Antibodies

TJ003234 High Dose for COVID-19

Phase 2 & 3
Waitlist Available
Research Sponsored by I-Mab Biopharma Co. Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 through day 30
Awards & highlights

Study Summary

This trial is testing a potential COVID-19 treatment to see if it is safe and effective. The treatment will be given to some people with COVID-19 to see if it reduces the levels of cytokines in their bodies.

Eligible Conditions
  • COVID-19

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 through day 30
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 through day 30 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Subjects Alive and Free of Mechanical Ventilation Among Subjects Who Are Free of Mechanical Ventilation at Baseline
Secondary outcome measures
All-cause Mortality Rate by Day 30
Length of Hospitalization
Percentage of Recovery by Day 14
+2 more

Side effects data

From 2022 Phase 2 & 3 trial • 149 Patients • NCT04341116
13%
ACUTE KIDNEY INJURY
13%
COVID-19
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo (Part 2)
TJ003234 3 mg/kg (Part 1)
TJ003234 6mg/kg (Part 1)
TJ003234 6 mg/kg (Part 2)
TJ003234 10mg/kg (Part 2)
Placebo (Part 1)

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: TJ003234 Medium DoseExperimental Treatment1 Intervention
Group II: TJ003234 Low DoseExperimental Treatment1 Intervention
Part 1 only
Group III: TJ003234 High DoseExperimental Treatment1 Intervention
Part 2 Phase 3 only
Group IV: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TJ003234
2019
Completed Phase 3
~190

Find a Location

Who is running the clinical trial?

I-Mab Biopharma Co. Ltd.Lead Sponsor
21 Previous Clinical Trials
2,334 Total Patients Enrolled
Claire Xu, MD, PhDStudy DirectorI-Mab Biopharma US Limited
2 Previous Clinical Trials
130 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
2020. "Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04341116.
~30 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top